Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Auris Medical Holding Ltd. announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity.
On Monday, the two companies forged a collaboration and license agreement that has the potential to be worth more than $450 million.
PharmaLink, Inc., an industry-leading pharmaceutical reverse distribution company, is announcing a series of initiatives designed to accommodate the changing dynamics of its business and the industry.
Parnell announces 2019 year-to-date revenue growth of 9% over the first 9 months of 2018, start of work on its new 2019 CMO contract, and updates to 2019 financial results.
Sumitovant will run as a wholly owned subsidiary of Sumitomo Dainippon Pharma.
There were a number of scandals in the biopharma industry that caught our attention in 2019. Here’s a look at four of them.
CELLINK’s production is completed in-house without middlemen – this unique advantage enables a workflow with high quality assurance and short lead times.
Cerecin, an innovative biopharmaceutical company focused on brain health, announced that Joseph S. Zakrzewski has joined the Company’s Board of Directors as Chairman.
Zelluna Immunotherapy announces the appointment of Namir Hassan as chief executive officer.
The Sartorius AI Lab (SAIL) conducts research in the use of artificial intelligence in Sartorius platform solutions for the biopharmaceutical industry